FDA Warning: Prolia | Medical News Bulletin


Patients with chronic kidney disease who use Prolia are at higher risk of developing dangerously low calcium levels, known as hypocalcemia. This can be particularly dangerous for patients undergoing dialysis or with mineral and bone density disorder. The FDA advises patients to contact their doctor to discuss the best medication regimen and be aware of symptoms such as confusion, seizures, irregular heart rhythm, fainting, and muscle weakness. It is important to not stop taking the medication without consulting a doctor and to maintain regular check-ups and calcium and vitamin D levels. The risk of rebound fractures is high if the medication is stopped abruptly.

Source link

error: Content is protected !!